COVID-19疫情期间患者对乳头乳晕复合体微色素沉着的看法
该研究通过问卷评估53例患者在2020年8月至9月期间对乳头乳晕复合体微色素沉着的看法,了解COVID-19疫情是否改变其寻求该治疗的态度。结果显示81.1%的患者认为疫情未影响其决定,相似比例的患者愿意在提问时继续治疗,凸显乳头乳晕复合体在乳房再造过程中的重要性。
要点
- 81.1%患者认为COVID-19未影响其接受微色素沉着的决定。
- 相似比例患者愿意在提问时继续接受该治疗。
- 结果凸显乳头乳晕复合体对患者再造历程的重要性。
核心结论
- 81.1%的患者报告COVID-19未影响其决定,相似比例的患者愿意在提问时继续治疗。
- 结果凸显乳头乳晕复合体对患者再造历程的重要性。
研究设计与样本
- 2020年8月至9月期间在微色素沉着门诊对53例患者进行问卷调查。
主要发现
- 81.1%的患者报告COVID-19未影响其决定。
- 相似比例的患者愿意在提问时继续治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Micropigmentation is a well-recognised option for nipple-areola complex reconstruction, as part of the breast reconstruction pathway for patients following mastectomy. As a part of delayed breast reconstruction, this treatment was put on hold during the COVID-19 pandemic. AIMS: To assess the views of patients regarding micropigmentation in response to the COVID-19 pandemic, and whether their attitudes to seeking out this part of the reconstructive journey had been altered. METHODS: A questionnaire undertaken with 53 patients between August & September 2020 attending the Micropigmentation clinic. FINDINGS: 81.1% of patients reported COVID-19 had not impacted their decision, with a similar proportion happy to proceed with the treatment at the time of questioning. CONCLUSIONS: The results highlight the importance of nipple-areola complex to our patients' reconstructive journey.
引用
- Frost S, Pilley M, Porter C, et al. Patient perspectives on nipple-areola complex micropigmentation during the COVID-19 pandemic. J Plast Reconstr Aesthet Surg. 2022. PMID: 35780000. doi:10.1016/j.bjps.2022.06.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。